Search results for abx831334

Brolucizumab, Abbexa, abx831334

Brolucizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting VEGFA, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Brolucizumab, also known as RTH258 or ESBA1008, 4 is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab was granted FDA approval in October 2019. 6.